An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

HIGHLIGHTS

• who: Styliani Karanika from the United Kingdom Stockholm University, Sweden have published the Article: An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis, in the Journal: (JOURNAL)
• what: The authors show that MIP-3a fusion and the IN route of delivery individually enhance the therapeutic adjunctive activity of a DNA vaccine targeting an Mtb persistence antigen in a murine model of chronic TB.
• how: Statistics Pairwise comparisons of group mean values for log10 CFU (microbiology data) and flow cytometry data were made using one-way analysis of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.